Search

Your search keyword '"Taphoorn, Martin J."' showing total 727 results
Start Over Author "Taphoorn, Martin J."
727 results on '"Taphoorn, Martin J."'

2. Health-Related Quality of Life in Intracranial Meningioma: Current Evidence and Future Directions

Author

Zamanipoor Najafabadi, Amir H., Dirven, Linda, Drummond, Katharine J., Taphoorn, Martin J. B., Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Steinlein, Ortrud, Series Editor, Xiao, Junjie, Series Editor, Zadeh, Gelareh, editor, Goldbrunner, Roland, editor, Krischek, Boris, editor, and Nassiri, Farshad, editor

Published
2023
Full Text
View/download PDF

4. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures

Author

Bui, Cat, Emechebe, Nnadozie, Kamalakar, Rajesh, Papadopoulos, Elektra, Sail, Kavita, Sen, Rohini, Turner, Sean C, Cocks, Kim, Reijneveld, Jaap, Gerlinger, Christoph, Keating, Karen, Su, Yun, Wolf, Birgit, Ge, Miaomiao, Ingelgaard, Anders, Peil, Barbara, Voorhaar, Maarten, Wong, Brendon, Dekanic Arbanas, Gracia, Kuljanic, Karin, Petranovic, Duska, Rede, Ivana, Arraras, Juan, Coons, Stephen Joel, Eremenco, Sonya, Murray, Lindsey, Reeve, Bryce, De Vries, Corinne, Herold, Ralf, Pignatti, Francesco, Machingura, Abigirl, Martinelli, Francesca, Musoro, Jammbe, Piccart, Martine, Barriuso, Jorge, Cherny, Nathan, Dafni, Ourania, De Vries, Elisabeth, Gyawali, Bishal, Kiesewetter, Barbara, Oosting, Sjoukje, Roitberg, Felipe, Rumpold, Gerhard, Schoepf, Felix, Tschuggnall, Michael, Black, Jennifer, Sasseville, Maxime, Soltys, Katherine, Ferrer, Montserrat, Garin, Olatz, Vilagut, Gemma, Schürmann, Christoph, Thomas, Stefanie, Wieseler, Beate, Snyder, Claire, Alonso Abad, Ariel, Bogaerts, Kris, Brackx, Febe, Molenberghs, Geert, Verbeke, Geert, Frigolett Catalan, Cristián, Choi, Jan, Thomassen, Doranne, Geissler, Jan, Sauerbrei, Willi, Gross, Franziska, Pilz, Micha Johannes, Barbachano, Yolanda, Campbell, Lisa, Rantell, Khadija, Desplanques, Gregoire, Regnault, Antoine, Morgan, Kate, Plate, Ananda, ten Seldam, Silene, Terada, Mitsumi, Mizusawa, Junki, Mitchell, Sandra, Wilder Smith, Ashley, Reksten, Tove Ragna, Schiel, Anja, Hansen Joseph, Kenth Louis, Campbell, Alicyn, Cappelleri, Joseph, de Besi, Patrizia, Russell-Smith, Alexander, Sandin, Rickard, Mamolo, Carla, Brundage, Michael, Tu, Dongsheng, Groenvold, Mogens, Petersen, Morten, Cleeland, Charlie, Williams, Lori, Shelley Wang, Xin, Ringash, Jolie, Calvert, Melanie, Cruz Rivera, Samantha, Aiyegbusi, Olalekan Lee, Goetghebeur, Els, Liu, Limin, Van Lancker, Kelly, Boele, Florien, Gilbert, Alexandra, Peacock, Rosemary, Basch, Ethan, King, Madeleine, Rutherford, Claudia, Bhatnagar, Vishal, Fiero, Mallorie, Horodniceanu, Erica, Johnson, Laura Lee, Kluetz, Paul, Rodriguez, Lisa, Pe, Madeline, Alanya, Ahu, Falk, Ragnhild Sorum, Amdal, Cecilie Delphin, Bjordal, Kristin, Chang, Jane, Cislo, Paul, Coens, Corneel, Dirven, Linda, Speck, Rebecca M, Fitzgerald, Kristina, Galinsky, Jayne, Giesinger, Johannes M, Holzner, Bernhard, Le Cessie, Saskia, O'Connor, Daniel, Oliver, Kathy, Pawar, Vivek, Quinten, Chantal, Schlichting, Michael, Ren, Jinma, Roychoudhury, Satrajit, Taphoorn, Martin J B, Velikova, Galina, Wintner, Lisa M, Griebsch, Ingolf, and Bottomley, Andrew

Published
2023
Full Text
View/download PDF

8. Influence of arterial transit time delays on the differentiation between tumor progression and pseudoprogression in glioblastoma by arterial spin labeling magnetic resonance imaging.

Author

van Dorth, Daniëlle, Jiang, Feng Yan, Schmitz‐Abecassis, Bárbara, Croese, Robert J. I., Taphoorn, Martin J. B., Smits, Marion, Koekkoek, Johan A. F., Dirven, Linda, de Bresser, Jeroen, and van Osch, Matthias J. P.

Subjects
MAGNETIC resonance imaging, SPIN labels, CANCER invasiveness, GLIOBLASTOMA multiforme, PERFUSION
Abstract

Arterial spin labeling (ASL) and dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) have shown potential for differentiating tumor progression from pseudoprogression. For pseudocontinuous ASL with a single postlabeling delay, the presence of delayed arterial transit times (ATTs) could affect the evaluation of ASL‐MRI perfusion data. In this study, the influence of ATT artifacts on the perfusion assessment and differentiation between tumor progression and pseudoprogression were studied. This study comprised 66 adult patients (mean age 60 ± 13 years; 40 males) with a histologically confirmed glioblastoma who received postoperative radio (chemo)therapy. ASL‐MRI and DSC‐MRI scans were acquired at 3 months postradiotherapy as part of the standard clinical routine. These scans were visually scored regarding (i) the severity of ATT artifacts (%) on the ASL‐MRI scans only, scored by two neuroradiologists; (ii) perfusion of the enhancing tumor lesion; and (iii) radiological evaluation of tumor progression versus pseudoprogression by one neuroradiologist. The final outcome was based on combined clinical and radiological follow‐up until 9 months postradiotherapy. ATT artifacts were identified in all patients based on the mean scores of two raters. A significant difference between the radiological evaluation of ASL‐MRI and DSC‐MRI was observed only for ASL images with moderate ATT severity (30%–65%). The perfusion assessment showed ASL‐MRI tending more towards hyperperfusion than DSC‐MRI in the case of moderate ATT artifacts. In addition, there was a significant difference between the prediction of tumor progression with ASL‐MRI and the final outcome in the case of severe ATT artifacts (McNemar test, p = 0.041). Despite using ASL imaging parameters close to the recommended settings, ATT artifacts frequently occur in patients with treated brain tumors. Those artifacts could hinder the radiological evaluation of ASL‐MRI data and the detection of true disease progression, potentially affecting treatment decisions for patients with glioblastoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

Author

Tesileanu, C. Mircea S., Vallentgoed, Wies R., Sanson, Marc, Taal, Walter, Clement, Paul M., Wick, Wolfgang, Brandes, Alba Ariela, Baurain, Jean Francais, Chinot, Olivier L., Wheeler, Helen, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Rudà, Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H., Caparrotti, Francesca, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Lim, Elizabeth, de Vos, Filip, Mulholland, Paul J., Taphoorn, Martin J. B., de Heer, Iris, Hoogstrate, Youri, de Wit, Maurice, Boggiani, Lorenzo, Venneker, Sanne, Oosting, Jan, Bovée, Judith V. M. G., Erridge, Sara, Vogelbaum, Michael A., Nowak, Anna K., Mason, Warren P., Kros, Johan M., Wesseling, Pieter, Aldape, Ken, Jenkins, Robert B., Dubbink, Hendrikus J., Baumert, Brigitta, Golfinopoulos, Vassilis, Gorlia, Thierry, van den Bent, Martin, and French, Pim J.

Published
2021
Full Text
View/download PDF

13. The outcomes measured and reported in intracranial meningioma clinical trials: A systematic review

Author

Millward, Christopher P; https://orcid.org/0000-0001-7727-1157, Keshwara, Sumirat M, Armstrong, Terri S; https://orcid.org/0000-0002-2414-0492, Barrington, Heather; https://orcid.org/0000-0001-9103-2670, Bell, Sabrina, Brodbelt, Andrew R, Bulbeck, Helen, Dirven, Linda; https://orcid.org/0000-0001-9157-9895, Grundy, Paul L, Islim, Abdurrahman I, Javadpour, Mohsen, Koszdin, Shelli D, Marson, Anthony G, McDermott, Michael W, Meling, Torstein R, Oliver, Kathy, Plaha, Puneet, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, Santarius, Thomas, Srikandarajah, Nisaharan; https://orcid.org/0000-0001-9578-508X, Taphoorn, Martin J B; https://orcid.org/0000-0001-9949-4722, Turner, Carole, Watts, Colin; https://orcid.org/0000-0003-3531-8791, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Williamson, Paula R, Zadeh, Gelareh; https://orcid.org/0000-0002-6637-4502, Zamanipoor Najafabadi, Amir H, Jenkinson, Michael D, Aldape, Kenneth; https://orcid.org/0000-0001-5119-7550, et al, Millward, Christopher P; https://orcid.org/0000-0001-7727-1157, Keshwara, Sumirat M, Armstrong, Terri S; https://orcid.org/0000-0002-2414-0492, Barrington, Heather; https://orcid.org/0000-0001-9103-2670, Bell, Sabrina, Brodbelt, Andrew R, Bulbeck, Helen, Dirven, Linda; https://orcid.org/0000-0001-9157-9895, Grundy, Paul L, Islim, Abdurrahman I, Javadpour, Mohsen, Koszdin, Shelli D, Marson, Anthony G, McDermott, Michael W, Meling, Torstein R, Oliver, Kathy, Plaha, Puneet, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, Santarius, Thomas, Srikandarajah, Nisaharan; https://orcid.org/0000-0001-9578-508X, Taphoorn, Martin J B; https://orcid.org/0000-0001-9949-4722, Turner, Carole, Watts, Colin; https://orcid.org/0000-0003-3531-8791, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Williamson, Paula R, Zadeh, Gelareh; https://orcid.org/0000-0002-6637-4502, Zamanipoor Najafabadi, Amir H, Jenkinson, Michael D, Aldape, Kenneth; https://orcid.org/0000-0001-5119-7550, and et al

Abstract

Background Meningioma clinical trials have assessed interventions including surgery, radiotherapy, and pharmacotherapy. However, agreement does not exist on what, how, and when outcomes of interest should be measured. To do so would allow comparative analysis of similar trials. This systematic review aimed to summarize the outcomes measured and reported in meningioma clinical trials. Methods Systematic literature and trial registry searches were performed to identify published and ongoing intracranial meningioma clinical trials (PubMed, Embase, Medline, CINAHL via EBSCO, and Web of Science, completed January 22, 2022). Reported outcomes were extracted verbatim, along with an associated definition and method of measurement if provided. Verbatim outcomes were deduplicated and the resulting unique outcomes were grouped under standardized outcome terms. These were classified using the taxonomy proposed by the “Core Outcome Measures in Effectiveness Trials” (COMET) initiative. Results Thirty published articles and 18 ongoing studies were included, describing 47 unique clinical trials: Phase 2 n = 33, phase 3 n = 14. Common interventions included: Surgery n = 13, radiotherapy n = 8, and pharmacotherapy n = 20. In total, 659 verbatim outcomes were reported, of which 84 were defined. Following de-duplication, 415 unique verbatim outcomes remained and were grouped into 115 standardized outcome terms. These were classified using the COMET taxonomy into 29 outcome domains and 5 core areas. Conclusions Outcome measurement across meningioma clinical trials is heterogeneous. The standardized outcome terms identified will be prioritized through an eDelphi survey and consensus meeting of key stakeholders (including patients), in order to develop a core outcome set for use in future meningioma clinical trials.

Published
2024

14. The outcomes measured and reported in observational studies of incidental and untreated intracranial meningioma: A systematic review

Author

Millward, Christopher P; https://orcid.org/0000-0001-7727-1157, Islim, Abdurrahman I, Armstrong, Terri S; https://orcid.org/0000-0002-2414-0492, Barrington, Heather; https://orcid.org/0000-0001-9103-2670, Bell, Sabrina, Brodbelt, Andrew R, Bulbeck, Helen, Dirven, Linda; https://orcid.org/0000-0001-9157-9895, Grundy, Paul L, Javadpour, Mohsen, Keshwara, Sumirat M, Koszdin, Shelli D, Marson, Anthony G, McDermott, Michael W, Meling, Torstein R, Oliver, Kathy, Plaha, Puneet, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, Santarius, Thomas, Srikandarajah, Nisaharan; https://orcid.org/0000-0001-9578-508X, Taphoorn, Martin J B; https://orcid.org/0000-0001-9949-4722, Turner, Carole, Watts, Colin; https://orcid.org/0000-0003-3531-8791, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Williamson, Paula R, Zadeh, Gelareh; https://orcid.org/0000-0002-6637-4502, Zamanipoor Najafabadi, Amir H, Jenkinson, Michael D, Aldape, Kenneth; https://orcid.org/0000-0001-5119-7550, et al, Millward, Christopher P; https://orcid.org/0000-0001-7727-1157, Islim, Abdurrahman I, Armstrong, Terri S; https://orcid.org/0000-0002-2414-0492, Barrington, Heather; https://orcid.org/0000-0001-9103-2670, Bell, Sabrina, Brodbelt, Andrew R, Bulbeck, Helen, Dirven, Linda; https://orcid.org/0000-0001-9157-9895, Grundy, Paul L, Javadpour, Mohsen, Keshwara, Sumirat M, Koszdin, Shelli D, Marson, Anthony G, McDermott, Michael W, Meling, Torstein R, Oliver, Kathy, Plaha, Puneet, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, Santarius, Thomas, Srikandarajah, Nisaharan; https://orcid.org/0000-0001-9578-508X, Taphoorn, Martin J B; https://orcid.org/0000-0001-9949-4722, Turner, Carole, Watts, Colin; https://orcid.org/0000-0003-3531-8791, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Williamson, Paula R, Zadeh, Gelareh; https://orcid.org/0000-0002-6637-4502, Zamanipoor Najafabadi, Amir H, Jenkinson, Michael D, Aldape, Kenneth; https://orcid.org/0000-0001-5119-7550, and et al

Abstract

Background The clinical management of patients with incidental intracranial meningioma varies markedly and is often based on clinician choice and observational data. Heterogeneous outcome measurement has likely hampered knowledge progress by preventing comparative analysis of similar cohorts of patients. This systematic review aimed to summarize the outcomes measured and reported in observational studies. Methods A systematic literature search was performed to identify published full texts describing active monitoring of adult cohorts with incidental and untreated intracranial meningioma (PubMed, EMBASE, MEDLINE, and CINAHL via EBSCO, completed January 24, 2022). Reported outcomes were extracted verbatim, along with an associated definition and method of measurement if provided. Verbatim outcomes were de-duplicated and the resulting unique outcomes were grouped under standardized outcome terms. These were classified using the taxonomy proposed by the “Core Outcome Measures in Effectiveness Trials” (COMET) initiative. Results Thirty-three published articles and 1 ongoing study were included describing 32 unique studies: study designs were retrospective n = 27 and prospective n = 5. In total, 268 verbatim outcomes were reported, of which 77 were defined. Following de-duplication, 178 unique verbatim outcomes remained and were grouped into 53 standardized outcome terms. These were classified using the COMET taxonomy into 9 outcome domains and 3 core areas. Conclusions Outcome measurement across observational studies of incidental and untreated intracranial meningioma is heterogeneous. The standardized outcome terms identified will be prioritized through an eDelphi survey and consensus meeting of key stakeholders (including patients), in order to develop a Core Outcome Set for use in future observational studies.

Published
2024

15. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Author

Weller, Michael, van den Bent, Martin, Preusser, Matthias, Le Rhun, Emilie, Tonn, Jörg C., Minniti, Giuseppe, Bendszus, Martin, Balana, Carmen, Chinot, Olivier, Dirven, Linda, French, Pim, Hegi, Monika E., Jakola, Asgeir S., Platten, Michael, Roth, Patrick, Rudà, Roberta, Short, Susan, Smits, Marion, Taphoorn, Martin J. B., von Deimling, Andreas, Westphal, Manfred, Soffietti, Riccardo, Reifenberger, Guido, and Wick, Wolfgang

Published
2021
Full Text
View/download PDF

17. Quality of Life and Cognition

Author

Coomans, Marijke B., Dirven, Linda, Taphoorn, Martin J. B., Tonn, Jörg-Christian, editor, Reardon, David A., editor, Rutka, James T., editor, and Westphal, Manfred, editor

Published
2019
Full Text
View/download PDF

19. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium

Author

Coens, Corneel, Pe, Madeline, Dueck, Amylou C, Sloan, Jeff, Basch, Ethan, Calvert, Melanie, Campbell, Alicyn, Cleeland, Charles, Cocks, Kim, Collette, Laurence, Devlin, Nancy, Dorme, Lien, Flechtner, Hans-Henning, Gotay, Carolyn, Griebsch, Ingolf, Groenvold, Mogens, King, Madeleine, Kluetz, Paul G, Koller, Michael, Malone, Daniel C, Martinelli, Francesca, Mitchell, Sandra A, Musoro, Jammbe Z, O'Connor, Daniel, Oliver, Kathy, Piault-Louis, Elisabeth, Piccart, Martine, Quinten, Chantal, Reijneveld, Jaap C, Schürmann, Christoph, Smith, Ashley Wilder, Soltys, Katherine M, Taphoorn, Martin J B, Velikova, Galina, and Bottomley, Andrew

Published
2020
Full Text
View/download PDF

20. Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Author

Weller, Michael, van den Bent, Martin, Preusser, Matthias, Le Rhun, Emilie, Tonn, Jörg C., Minniti, Giuseppe, Bendszus, Martin, Balana, Carmen, Chinot, Olivier, Dirven, Linda, French, Pim, Hegi, Monika E., Jakola, Asgeir S., Platten, Michael, Roth, Patrick, Rudà, Roberta, Short, Susan, Smits, Marion, Taphoorn, Martin J. B., von Deimling, Andreas, Westphal, Manfred, Soffietti, Riccardo, Reifenberger, Guido, and Wick, Wolfgang

Published
2022
Full Text
View/download PDF

23. MRI phenotypes of glioblastomas early after treatment are suggestive of overall patient survival

Author

Abecassis, Bárbara Schmitz-, primary, Dirven, Linda, additional, Jiang, Janey, additional, Keller, Jasmin A, additional, Croese, Robert J I, additional, van Dorth, Daniëlle, additional, Ghaznawi, Rashid, additional, Kant, Ilse M J, additional, Taphoorn, Martin J B, additional, van Osch, Matthias J P, additional, Koekkoek, Johan A F, additional, and de Bresser, Jeroen, additional

Published
2023
Full Text
View/download PDF

28. Healthcare utilization and costs among intracranial meningioma patients during long-term follow-up

Author

Huynh, Kevin A., Coopmans, Eva C., Najafabadi, Amir H. Z., Dirven, Linda, Peerdeman, Saskia M., Biermasz, Nienke R., Verstegen, Marco J. T., van Furth, Wouter R., Boele, Florien W., Klein, Martin, Koekkoek, Johan, Lagerwaard, Frank, van der Meer, Pim B., Taphoorn, Martin J. B., Moojen, Wouter A., Reijneveld, Jaap C., Neurology, Neurosurgery, AII - Cancer immunology, CCA - Cancer biology and immunology, Medical psychology, CCA - Cancer Treatment and quality of life, Radiation Oncology, and CCA - Imaging and biomarkers

Subjects
Cancer Research, Neurology, Oncology, Neurology (clinical)
Abstract

Purpose Few studies have reported on healthcare utilization and costs for intracranial meningioma patients, while the tumor and its treatment profoundly affect patients’ functioning and well-being. Here we evaluated healthcare utilization and costs, including their determinants. Methods A multicenter cross-sectional study of adult meningioma patients ≥ 5 years after intervention. Patients completed three validated patient-reported outcome measures (PROMs) assessing patients ‘functioning and wellbeing (SF-36, EORTC QLQ-BN20, and HADS) and a study-specific questionnaire assessing healthcare utilization over the previous twelve months. Healthcare costs of the twelve months prior were calculated using reported healthcare utilization ≥ 5 years after intervention by the Dutch Manual for Economic Evaluation in Healthcare. Determinants for healthcare utilization and costs were determined with regression analyses. Results We included 190 patients with WHO grade I or II meningioma after a mean follow-up since intervention of 9.2 years (SD 4.0). The general practitioner (80.5%), physiotherapist (37.9%), and neurologist (25.4%) were visited most often by patients. Median annual healthcare costs were €871 (IQR €262–€1933). Main contributors to these costs were medication (45.8% of total costs, of which anti-seizure medication was utilized most [21.6%]), specialist care (17.7%), and physiotherapy (15.5%). Lower HRQoL was a significant determinant for higher healthcare utilization and costs. Conclusion In patients with meningioma, medication costs constituted the largest expenditure of total healthcare costs, in particular anti-seizure medication. Particularly a lower HRQoL was a determinant for healthcare utilization and costs. A patient-specific approach aimed at improving patients’ HRQoL and needs could be beneficial in reducing disease burden and functional recovery.

Published
2023

30. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures

Author

Pe, Madeline, primary, Alanya, Ahu, additional, Falk, Ragnhild Sorum, additional, Amdal, Cecilie Delphin, additional, Bjordal, Kristin, additional, Chang, Jane, additional, Cislo, Paul, additional, Coens, Corneel, additional, Dirven, Linda, additional, Speck, Rebecca M, additional, Fitzgerald, Kristina, additional, Galinsky, Jayne, additional, Giesinger, Johannes M, additional, Holzner, Bernhard, additional, Le Cessie, Saskia, additional, O'Connor, Daniel, additional, Oliver, Kathy, additional, Pawar, Vivek, additional, Quinten, Chantal, additional, Schlichting, Michael, additional, Ren, Jinma, additional, Roychoudhury, Satrajit, additional, Taphoorn, Martin J B, additional, Velikova, Galina, additional, Wintner, Lisa M, additional, Griebsch, Ingolf, additional, Bottomley, Andrew, additional, Bui, Cat, additional, Emechebe, Nnadozie, additional, Kamalakar, Rajesh, additional, Papadopoulos, Elektra, additional, Sail, Kavita, additional, Sen, Rohini, additional, Turner, Sean C, additional, Cocks, Kim, additional, Reijneveld, Jaap, additional, Gerlinger, Christoph, additional, Keating, Karen, additional, Su, Yun, additional, Wolf, Birgit, additional, Ge, Miaomiao, additional, Ingelgaard, Anders, additional, Peil, Barbara, additional, Voorhaar, Maarten, additional, Wong, Brendon, additional, Dekanic Arbanas, Gracia, additional, Kuljanic, Karin, additional, Petranovic, Duska, additional, Rede, Ivana, additional, Arraras, Juan, additional, Coons, Stephen Joel, additional, Eremenco, Sonya, additional, Murray, Lindsey, additional, Reeve, Bryce, additional, De Vries, Corinne, additional, Herold, Ralf, additional, Pignatti, Francesco, additional, Machingura, Abigirl, additional, Martinelli, Francesca, additional, Musoro, Jammbe, additional, Piccart, Martine, additional, Barriuso, Jorge, additional, Cherny, Nathan, additional, Dafni, Ourania, additional, De Vries, Elisabeth, additional, Gyawali, Bishal, additional, Kiesewetter, Barbara, additional, Oosting, Sjoukje, additional, Roitberg, Felipe, additional, Rumpold, Gerhard, additional, Schoepf, Felix, additional, Tschuggnall, Michael, additional, Black, Jennifer, additional, Sasseville, Maxime, additional, Soltys, Katherine, additional, Ferrer, Montserrat, additional, Garin, Olatz, additional, Vilagut, Gemma, additional, Schürmann, Christoph, additional, Thomas, Stefanie, additional, Wieseler, Beate, additional, Snyder, Claire, additional, Alonso Abad, Ariel, additional, Bogaerts, Kris, additional, Brackx, Febe, additional, Molenberghs, Geert, additional, Verbeke, Geert, additional, Frigolett Catalan, Cristián, additional, Choi, Jan, additional, Thomassen, Doranne, additional, Geissler, Jan, additional, Sauerbrei, Willi, additional, Gross, Franziska, additional, Pilz, Micha Johannes, additional, Barbachano, Yolanda, additional, Campbell, Lisa, additional, Rantell, Khadija, additional, Desplanques, Gregoire, additional, Regnault, Antoine, additional, Morgan, Kate, additional, Plate, Ananda, additional, ten Seldam, Silene, additional, Terada, Mitsumi, additional, Mizusawa, Junki, additional, Mitchell, Sandra, additional, Wilder Smith, Ashley, additional, Reksten, Tove Ragna, additional, Schiel, Anja, additional, Hansen Joseph, Kenth Louis, additional, Campbell, Alicyn, additional, Cappelleri, Joseph, additional, de Besi, Patrizia, additional, Russell-Smith, Alexander, additional, Sandin, Rickard, additional, Mamolo, Carla, additional, Brundage, Michael, additional, Tu, Dongsheng, additional, Groenvold, Mogens, additional, Petersen, Morten, additional, Cleeland, Charlie, additional, Williams, Lori, additional, Shelley Wang, Xin, additional, Ringash, Jolie, additional, Calvert, Melanie, additional, Cruz Rivera, Samantha, additional, Aiyegbusi, Olalekan Lee, additional, Goetghebeur, Els, additional, Liu, Limin, additional, Van Lancker, Kelly, additional, Boele, Florien, additional, Gilbert, Alexandra, additional, Peacock, Rosemary, additional, Basch, Ethan, additional, King, Madeleine, additional, Rutherford, Claudia, additional, Bhatnagar, Vishal, additional, Fiero, Mallorie, additional, Horodniceanu, Erica, additional, Johnson, Laura Lee, additional, Kluetz, Paul, additional, and Rodriguez, Lisa, additional

Published
2023
Full Text
View/download PDF

31. The prevalence and severity of fatigue in meningioma patients and its association with patient-, tumor- and treatment-related factors

Author

Quach, Kwong T, primary, Dirven, Linda, additional, Vingerhoed, Aliede M, additional, de Bresser, Jeroen, additional, Dammers, Ruben, additional, Bos, Eelke M, additional, Moojen, Wouter A, additional, Peul, Wilco C, additional, Taphoorn, Martin J B, additional, Zamanipoor Najafabadi, Amir H, additional, and van Furth, Wouter R, additional

Published
2023
Full Text
View/download PDF

33. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

Author

Weller, Michael, van den Bent, Martin, Tonn, Jörg C, Stupp, Roger, Preusser, Matthias, Cohen-Jonathan-Moyal, Elizabeth, Henriksson, Roger, Rhun, Emilie Le, Balana, Carmen, Chinot, Olivier, Bendszus, Martin, Reijneveld, Jaap C, Dhermain, Frederick, French, Pim, Marosi, Christine, Watts, Colin, Oberg, Ingela, Pilkington, Geoffrey, Baumert, Brigitta G, Taphoorn, Martin J B, Hegi, Monika, Westphal, Manfred, Reifenberger, Guido, Soffietti, Riccardo, and Wick, Wolfgang

Published
2017
Full Text
View/download PDF

34. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards

Author

Bottomley, Andrew, Pe, Madeline, Sloan, Jeff, Basch, Ethan, Bonnetain, Franck, Calvert, Melanie, Campbell, Alicyn, Cleeland, Charles, Cocks, Kim, Collette, Laurence, Dueck, Amylou C, Devlin, Nancy, Flechtner, Hans-Henning, Gotay, Carolyn, Greimel, Eva, Griebsch, Ingolf, Groenvold, Mogens, Hamel, Jean-Francois, King, Madeleine, Kluetz, Paul G, Koller, Michael, Malone, Daniel C, Martinelli, Francesca, Mitchell, Sandra A, Moinpour, Carol M, Musoro, Jammbe, O’Connor, Daniel, Oliver, Kathy, Piault-Louis, Elisabeth, Piccart, Martine, Pimentel, Francisco L, Quinten, Chantal, Reijneveld, Jaap C, Schürmann, Christoph, Smith, Ashley Wilder, Soltys, Katherine M, Taphoorn, Martin J B, Velikova, Galina, and Coens, Corneel

Published
2016
Full Text
View/download PDF

35. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Author

Baumert, Brigitta G, Hegi, Monika E, van den Bent, Martin J, von Deimling, Andreas, Gorlia, Thierry, Hoang-Xuan, Khê, Brandes, Alba A, Kantor, Guy, Taphoorn, Martin J B, Hassel, Mohamed Ben, Hartmann, Christian, Ryan, Gail, Capper, David, Kros, Johan M, Kurscheid, Sebastian, Wick, Wolfgang, Enting, Roelien, Reni, Michele, Thiessen, Brian, Dhermain, Frederic, Bromberg, Jacoline E, Feuvret, Loic, Reijneveld, Jaap C, Chinot, Olivier, Gijtenbeek, Johanna M M, Rossiter, John P, Dif, Nicolas, Balana, Carmen, Bravo-Marques, Jose, Clement, Paul M, Marosi, Christine, Tzuk-Shina, Tzahala, Nordal, Robert A, Rees, Jeremy, Lacombe, Denis, Mason, Warren P, and Stupp, Roger

Published
2016
Full Text
View/download PDF

36. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Author

Reijneveld, Jaap C, Taphoorn, Martin J B, Coens, Corneel, Bromberg, Jacoline E C, Mason, Warren P, Hoang-Xuan, Khê, Ryan, Gail, Hassel, Mohamed Ben, Enting, Roelien H, Brandes, Alba A, Wick, Antje, Chinot, Olivier, Reni, Michele, Kantor, Guy, Thiessen, Brian, Klein, Martin, Verger, Eugenie, Borchers, Christian, Hau, Peter, Back, Michael, Smits, Anja, Golfinopoulos, Vassilis, Gorlia, Thierry, Bottomley, Andrew, Stupp, Roger, and Baumert, Brigitta G

Published
2016
Full Text
View/download PDF

38. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033

Author

Bady, Pierre, Kurscheid, Sebastian, Delorenzi, Mauro, Gorlia, Thierry, van den Bent, Martin J., Hoang-Xuan, Khê, Vauléon, Élodie, Gijtenbeek, Anja, Enting, Roelien, Thiessen, Brian, Chinot, Olivier, Dhermain, Frédéric, Brandes, Alba A., Reijneveld, Jaap C., Marosi, Christine, Taphoorn, Martin J. B., Wick, Wolfgang, von Deimling, Andreas, French, Pim, Stupp, Roger, Baumert, Brigitta G., and Hegi, Monika E.

Published
2018
Full Text
View/download PDF

39. Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence

Author

Draaisma, Kaspar, Tesileanu, C Mircea S, de Heer, Iris, Klein, Martin, Smits, Marion, Reijneveld, Jaap C, Clement, Paul M, de Vos, Filip Y F, Wick, Antje, Mulholland, Paul J, Taphoorn, Martin J B, Weller, Michael, Chinot, Olivier L, Kros, Johan M, Verschuere, Tina, Coens, Corneel, Golfinopoulos, Vassilis, Gorlia, Thierry, Idbaih, Ahmed, Robe, Pierre A, van den Bent, Martin J, French, Pim J, Medical psychology, Neurology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, Radiology & Nuclear Medicine, Pathology, University of Zurich, and French, Pim J

Subjects
Cancer Research, Brain Neoplasms, Homozygote, 610 Medicine & health, Glioma, DNA Methylation, Prognosis, Magnetic Resonance Imaging, Isocitrate Dehydrogenase, 10040 Clinic for Neurology, DNA Repair Enzymes, Oncology, SDG 3 - Good Health and Well-being, Mutation, Humans, 2730 Oncology, 1306 Cancer Research, Neoplasm Recurrence, Local, DNA Modification Methylases, Sequence Deletion
Abstract

Purpose: Despite recent advances in the molecular characterization of gliomas, it remains unclear which patients benefit most from which second-line treatments. The TAVAREC trial was a randomized, open-label phase II trial assessing the benefit of the addition of the angiogenesis inhibitor bevacizumab to treatment with temozolomide in patients with a first enhancing recurrence of World Health Organization grade 2 or 3 glioma without 1p/19q codeletion. We evaluated the prognostic significance of genome-wide DNA methylation profiles and copy-number variations on the TAVAREC trial samples. Experimental Design: Isocitrate dehydrogenase (IDH) mutation status was determined via Sanger sequencing and IHC. DNA methylation analysis was performed using the MethylationEPIC BeadChip (Illumina) from which 1p/19q codeletion, MGMT promoter methylation (MGMT-STP27), and homozygous deletion of CDKN2A/B were determined. DNA methylation classes were determined according to classifiers developed in Heidelberg and The Cancer Genome Atlas (TCGA; “Heidelberg” and “TCGA” classifier respectively). Results: DNA methylation profiles of 122 samples were successfully determined. As expected, most samples were IDH-mutant (89/122) and MGMT promotor methylated (89/122). Methylation classes were prognostic for time to progression. However, Heidelberg methylation classes determined at time of diagnosis were no longer prognostic following enhancing recurrence of the tumor. In contrast, TCGA methylation classes of primary samples remained prognostic also following enhancing recurrence. Homozygous deletions in CDKN2A/B were found in 10 of 87 IDH-mutated samples and were prognostically unfavorable at recurrence. Conclusions: DNA methylome Heidelberg classification at time of diagnosis is no longer of prognostic value at the time of enhancing recurrence. CDKN2A/B deletion status was predictive of survival from progression of IDH-mutated tumors.

Published
2022

41. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

Author

Hoang-Xuan, Khê, Deckert, Martina, Ferreri, Andrés J M, Furtner, Julia, Gallego Perez-Larraya, Jaime, Henriksson, Roger, Hottinger, Andreas F., Kasenda, Benjamin, Lefranc, Florence, Lossos, Alexander, McBain, Catherine, Preusser, Matthias, Roth, Patrick, Rudà, Roberta, Schlegel, Uwe, Soffietti, Riccardo, Soussain, Carole, Taphoorn, Martin J B, Touitou, Valérie, Weller, Michael, Bromberg, Jacoline E C, Hoang-Xuan, Khê, Deckert, Martina, Ferreri, Andrés J M, Furtner, Julia, Gallego Perez-Larraya, Jaime, Henriksson, Roger, Hottinger, Andreas F., Kasenda, Benjamin, Lefranc, Florence, Lossos, Alexander, McBain, Catherine, Preusser, Matthias, Roth, Patrick, Rudà, Roberta, Schlegel, Uwe, Soffietti, Riccardo, Soussain, Carole, Taphoorn, Martin J B, Touitou, Valérie, Weller, Michael, and Bromberg, Jacoline E C

Abstract

The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.

Published
2023
Full Text
View/download PDF

42. Cognitive outcomes after multimodal treatment in adult glioma patients: A meta-analysis

Author

De Roeck, Laurien, Gillebert, R Céline, van Aert, Robbie C M, Vanmeenen, Amber, Klein, Martin, Taphoorn, Martin J B, Gehring, Karin, Lambrecht, Maarten, Sleurs, Charlotte, De Roeck, Laurien, Gillebert, R Céline, van Aert, Robbie C M, Vanmeenen, Amber, Klein, Martin, Taphoorn, Martin J B, Gehring, Karin, Lambrecht, Maarten, and Sleurs, Charlotte

Abstract

Purpose: Cognitive functioning is increasingly assessed as a secondary outcome in neuro-oncological trials. However, which cognitive domains or tests to assess, remains debatable. In this meta-analysis, we aimed to elucidate the longer-term test-specific cognitive outcomes in adult glioma patients.Methods: A systematic search yielded 7098 articles for screening. To investigate cognitive changes in glioma patients and differences between patients and controls ≥one-year follow-up, random-effects meta-analyses were conducted per cognitive test, separately for studies with a longitudinal and cross-sectional design. A meta-regression analysis with a moderator for interval testing (additional cognitive testing between baseline and one-year post-treatment) was performed to investigate the impact of practice in longitudinal designs.Results: Eighty-three studies were reviewed, of which 37 were analyzed in the meta-analysis, involving 4078 patients. In longitudinal designs, semantic fluency was the most sensitive test to detect cognitive decline over time. Cognitive performance on MMSE, digit span forward, phonemic and semantic fluency declined over time in patients who had no interval testing. In cross-sectional studies, patients performed worse than controls on the MMSE, digit span backward, semantic fluency, Stroop speed interference task, trail making test B and finger tapping.Conclusion: Cognitive performance of glioma patients one year after treatment is significantly lower compared to the norm, with specific tests potentially being more sensitive. Cognitive decline over time occurs as well, but can easily be overlooked in longitudinal designs due to practice effects (as a result of interval testing). It is warranted to sufficiently correct for practice effects in future longitudinal trials.

Published
2023

43. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time:A synthesis across 21 clinical trials involving nine different cancer types

Author

Musoro, Jammbe Z, Coens, Corneel, Sprangers, Mirjam A G, Brandberg, Yvonne, Groenvold, Mogens, Flechtner, Hans-Henning, Cocks, Kim, Velikova, Galina, Dirven, Linda, Greimel, Elfriede, Singer, Susanne, Pogoda, Katarzyna, Gamper, Eva M, Sodergren, Samantha C, Eggermont, Alexander, Koller, Michael, Reijneveld, Jaap C, Taphoorn, Martin J B, King, Madeleine T, Bottomley, Andrew, Musoro, Jammbe Z, Coens, Corneel, Sprangers, Mirjam A G, Brandberg, Yvonne, Groenvold, Mogens, Flechtner, Hans-Henning, Cocks, Kim, Velikova, Galina, Dirven, Linda, Greimel, Elfriede, Singer, Susanne, Pogoda, Katarzyna, Gamper, Eva M, Sodergren, Samantha C, Eggermont, Alexander, Koller, Michael, Reijneveld, Jaap C, Taphoorn, Martin J B, King, Madeleine T, and Bottomley, Andrew

Abstract

INTRODUCTION: Early guidelines for minimally important differences (MIDs) for the EORTC QLQ-C30 proposed ≥10 points change as clinically meaningful for all scales. Increasing evidence that MIDs can vary by scale, direction of change, cancer type and estimation method has raised doubt about a single global standard. This paper identifies MID patterns for interpreting group-level change in EORTC QLQ-C30 scores across nine cancer types.METHODS: Data were obtained from 21 published EORTC Phase III trials that enroled 13,015 patients across nine cancer types (brain, colorectal, advanced breast, head/neck, lung, mesothelioma, melanoma, ovarian, and prostate). Anchor-based MIDs for within-group change and between-group differences in change over time were obtained via mean change method and linear regression, respectively. Separate MIDs were estimated for improvements and deteriorations. Distribution-based estimates were derived and compared with anchor-based MIDs.RESULTS: Anchor-based MIDs mostly ranged from 5 to 10 points. Differences in MIDs for improvement vs deterioration, for both within-group and between-group, were mostly within a 2-points range. Larger differences between within-group and between-group MIDs were observed for several scales in ovarian, lung and head/neck cancer. Most anchor-based MIDs ranged between 0.3 SD and 0.5 SD distribution-based estimates.CONCLUSIONS: Our results reinforce recent claims that no single MID can be applied to all EORTC QLQ-C30 scales and disease settings. MIDs varied by scale, improvement/deterioration, within/between comparisons and by cancer type. Researchers applying commonly used rules of thumb must be aware of the risk of dismissing changes that are clinically meaningful or underpowering analyses when smaller MIDs apply.

Published
2023

44. Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: a longitudinal study spanning two decades

Author

Pathologie Pathologen staf, Brain, Cancer, Neurologen, Boele, Florien W, den Otter, Patricia W M, Reijneveld, Jaap C, de Witt Hamer, Philip C, van Thuijl, Hinke F, Lorenz, Linda M C, Wesseling, Pieter, Lagerwaard, Frank J, Taphoorn, Martin J B, Kouwenhoven, Mathilde C M, Snijders, Tom J, Douw, Linda, Klein, Martin, Pathologie Pathologen staf, Brain, Cancer, Neurologen, Boele, Florien W, den Otter, Patricia W M, Reijneveld, Jaap C, de Witt Hamer, Philip C, van Thuijl, Hinke F, Lorenz, Linda M C, Wesseling, Pieter, Lagerwaard, Frank J, Taphoorn, Martin J B, Kouwenhoven, Mathilde C M, Snijders, Tom J, Douw, Linda, and Klein, Martin

Published
2023

45. IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas

Author

van Opijnen, Mark P., Tesileanu, C. Mircea S., Dirven, Linda, van der Meer, Pim B., Wijnenga, Maarten M. J., Vincent, Arnaud J. P. E., Broekman, Marike L. D., Dubbink, Hendrikus J., Kros, Johan M., van Duinen, Sjoerd G., Smits, Marion, French, Pim J., van den Bent, Martin J., Taphoorn, Martin J. B., Koekkoek, Johan A. F., van Opijnen, Mark P., Tesileanu, C. Mircea S., Dirven, Linda, van der Meer, Pim B., Wijnenga, Maarten M. J., Vincent, Arnaud J. P. E., Broekman, Marike L. D., Dubbink, Hendrikus J., Kros, Johan M., van Duinen, Sjoerd G., Smits, Marion, French, Pim J., van den Bent, Martin J., Taphoorn, Martin J. B., and Koekkoek, Johan A. F.

Abstract

Background IDH1/2 wildtype (IDHwt) glioma WHO grade 2 and 3 patients with pTERT mutation and/or EGFR amplification and/or + 7/-10 chromosome gain/loss have a similar overall survival time as IDHwt glioblastoma patients, and are both considered glioblastoma IDHwt according to the WHO 2021 classification. However, differences in seizure onset have been observed. This study aimed to compare the course of epilepsy in the 2 glioblastoma subtypes. Methods We analyzed epilepsy data of an existing cohort including IDHwt histologically lower-grade glioma WHO grade 2 and 3 with molecular glioblastoma-like profile (IDHwt hLGG) and IDHwt glioblastoma patients. Primary outcome was the incidence proportion of epilepsy during the disease course. Secondary outcomes included, among others, onset of epilepsy, number of seizure days, and antiepileptic drug (AED) polytherapy. Results Out of 254 patients, 78% (50/64) IDHwt hLGG and 68% (129/190) IDHwt glioblastoma patients developed epilepsy during the disease (P = .121). Epilepsy onset before histopathological diagnosis occurred more frequently in IDHwt hLGG compared to IDHwt glioblastoma patients (90% vs 60%, P < .001), with a significantly longer median time to diagnosis (3.5 vs 1.3 months, P < .001). Median total seizure days was also longer for IDHwt hLGG patients (7.0 vs 3.0, P = .005), and they received more often AED polytherapy (32% vs 17%, P = .028). Conclusions Although the incidence proportion of epilepsy during the entire disease course is similar, IDHwt hLGG patients show a significantly higher incidence of epilepsy before diagnosis and a significantly longer median time between first seizure and diagnosis compared to IDHwt glioblastoma patients, indicating a distinct clinical course.

Published
2023

47. Minimally Important Differences for Interpreting ORTC QLQ-C30 Change Scores Over Time: A Synthesis Across 21 Clinical Trials Involving Nine Different Cancer Types

Author

Musoro, Jammbe Z., primary, Coens, Corneel, additional, Sprangers, Mirjam A. G., additional, Brandberg, Yvonne, additional, Groenvold, Mogens, additional, Flechtner, Hans-Henning, additional, Cocks, Kim, additional, Velikova, Galina, additional, Dirven, Linda, additional, Greimel, Elfriede, additional, Singer, Susanne, additional, Pogoda, Katarzyna, additional, Gamper, Eva M., additional, Sodergren, Samantha C., additional, Eggermont, Alexander M.M., additional, Koller, Michael, additional, Reijneveld, Jaap C., additional, Taphoorn, Martin J. B., additional, King, Madeleine T., additional, and Bottomley, Andrew, additional

Published
2023
Full Text
View/download PDF

48. Health-Related Quality of Life Results from the Randomized Phase Ii Tavarec Trial on Temozolomide With or Without Bevacizumab in 1p/19q Intact First Recurrence Who Grade 2 and 3 Glioma (Eortc 26091)

Author

Reijneveld, Jaap C., primary, Machingura, Abigirl, additional, Coens, Corneel, additional, Taphoorn, Martin J. B., additional, Taal, Walter, additional, Clement, Paul M., additional, Idbaih, Ahmed, additional, de Vos, Filip Y. F., additional, Klein, Martin, additional, Wick, Wolfgang, additional, Mulholland, Paul J., additional, Lewis, Joanne, additional, Golfinopoulos, Vassilis, additional, Ghislain, Irina, additional, Bottomley, Andrew, additional, van den Bent, Martin, additional, and Group, EORTC Brain Tumor, additional

Published
2023
Full Text
View/download PDF

49. Corrigendum to: Palliative care and end-of-life care in adults with malignant brain tumors

Author

Koekkoek, Johan A F, primary, van der Meer, Pim B, additional, Pace, Andrea, additional, Hertler, Caroline, additional, Harrison, Rebecca, additional, Leeper, Heather E, additional, Forst, Deborah A, additional, Jalali, Rakesh, additional, Oliver, Kathy, additional, Philip, Jennifer, additional, Taphoorn, Martin J B, additional, Dirven, Linda, additional, and Walbert, Tobias, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results